anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cobimetinib will be administered at a maximal dose of 60 mg daily for 21 days on, then 7 days off, in a 28-Day treatment cycle for 12 cycles (approximately 12 months). Cobimetinib should be taken once daily at approximately the same time each day, and no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal. Cobimetinib tablets should never be chewed, cut, or crushed. Therapy may continue for up to 12 cycles provided the subject meets the criteria for starting subsequent cycles and does not meet any of the criteria for cobimetinib discontinuation. At least 7 days off cobimetinib (within +7 days) is required prior to starting a new treatment cycle.
The recommended adult oral dosage for the treatment of erosive esophagitis that has been diagnosed by endoscopy is 1,600 mg daily in divided doses (800 mg twice daily or 400 mg 4 times daily) for 12 weeks. The use of cimetidine tablets beyond 12 weeks has not been established.

Pathological Hypersecretory Conditions (such as Zollinger-Ellison Syndrome)

Recommended adult oral dosage: 300 mg 4 times a day with meals and at bedtime. In some patients it may be necessary to administer higher doses more frequently. Doses should be adjusted to individual patient needs, but should not usually exceed 2,400 mg per day and should continue as long as clinically indicated.

Dosage Adjustment for Patients with Impaired Renal Function

Patients with severely impaired renal function have been treated with cimetidine tablets. However, such usage has been very limited. On the basis of this experience the recommended dosage is 300 mg every 12 hours orally. Should the patient’s condition require, the frequency of dosing may be increased to every 8 hours or even further with caution. In severe renal failure, accumulation may occur and the lowest frequency of dosing compatible with an adequate patient response should be used. When liver impairment is also present, further reductions in dosage may be necessary. Hemodialysis reduces the level of circulating cimetidine tablets. Ideally, the dosage schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.
Eligible subjects received Bevacizumab in combination with Oxaliplatin and the TAS-102 investigational drug, and Bevacizumab and Oxaliplatin were administered intravenously on day 1 of each cycle. Medicine, every 14 days as a course of treatment, TAS-102 orally administered, 35mg/m2 (maximum single dose 80mg), bid, orally on the 1st to 5th days, 2 weeks as a course of treatment.

Patients were treated until objective disease progression, worsening symptoms, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first. Clinicians will comprehensively evaluate according to clinical treatment guidelines and clinical practice treatment principles. For patients who still benefit after progression, the investigator can decide whether to continue the treatment with Bevacizumab combined with Oxaliplatin and TAS-102. Efficacy objectives were assessed after all subjects completed treatment/termination visits. Subjects were assessed for safety throughout the study period through laboratory tests and adverse event reporting.
Every structure might be exposed to fire at some point in its lifecycle. The ability of geopolymer composites to withstand the effects of fire damage early before it is put out is of great importance. This study examined the effects of fire on geopolymer composite samples made with high-calcium fly ash and alkaline solution synthesised from waste banana peduncle and silica fume. A ratio of 0.30, 0.35, and 0.4 was used in the study for the alkaline solution to fly ash. Also used were ratios of 0.5, 0.75, and 1 for silica oxide (silica fume) to potassium hydroxide ratio. The strength loss, residual compressive strength, percentage strength loss, relative residual compressive strength, ultrasonic pulse velocity, and microstructural properties of the thirteen mortar mixes were measured after exposure to temperatures of 200, 400, 600, and 800 °C for 1 h, respectively. The results reveal that geopolymer samples exposed to elevated temperatures showed great dimensional stability with no visible surface cracks. There was a colour transition from dark grey to whitish brown for the green geopolymer mortar and brown to whitish brown for the control sample. As the temperature rose, weight loss became more pronounced, with 800 °C producing the most significant weight reduction. The optimum mixes had a residual compressive strength of 25.02 MPa after being exposed to 200 °C, 18.72 MPa after being exposed to 400 °C, 14.04 MPa after being exposed to 600 °C, and 7.41 MPa after being exposed to 800 °C. The control had a residual compressive strength of 8.45 MPa after being exposed to 200 °C, 6.67 MPa after being exposed to 400 °C, 3.16 MPa after being exposed to 600 °C, and 2.23 MPa after being exposed to 800 °C. The relative residual compressive strength decreases for green geopolymer mortar are most significant at 600 and 800 °C, with an average decrease of 0.47 and 0.30, respectively. The microstructure of the samples revealed various phase changes and new product formations as the temperature increased.
ABSTRACT The present invention is directed to the measurement of soluble T cell growth factor receptors, soluble T cell differentiation antigens, or related soluble molecules or fragments thereof, and the use of such measurements in the diagnosis and therapy of diseases and disorders. The measurement of such molecules can be valuable in monitoring the effect of a therapeutic treatment on a subject, detecting and/or staging a disease in a subject, and in differential diagnosis of a physiological condition in a subject. These measurements can also aid in predicting therapeutic outcome and in evaluating and monitoring the immune status of patients. In specific embodiments, measurements of serum or plasma interleukin-2 receptor levels can be made, to detect or stage leukemia or lymphoma. In other embodiments, IL2R levels, or CD8 levels, can be used to differentially diagnose renal allograft rejection, as distinguished from Cyclosporin A nephrotoxicity. In another embodiment, CD8 levels can be measured to differentially diagnose rheumatoid arthritis, as distinct from other joint diseases. In particular embodiments, measurements of the soluble T cell surface molecules can be accomplished by sandwich enzyme immunuoassays.
Participants with major depressive disorder receive no treatment but are monitored closely for 8 weeks. Participants in this arm are offered the treatment at the end of the study.
Provided is an agent for the prevention and/or treatment of Porphyromonas gingivalis infection. An agent for the prevention and/or treatment of Porphyromonas gingivalis infection that contains killed Enterococcus faecalis. An agent for the prevention and/or treatment of a disease caused by Porphyromonas gingivalis that contains killed Enterococcus faecalis. A drug or a food for the prevention and/or treatment of Porphyromonas gingivalis infection that contains killed Enterococcus faecalis. A drug or a food for the prevention and/or treatment of a disease caused by of Porphyromonas gingivalis that contains killed Enterococcus faecalis. A Porphyromonas gingivalis growth inhibitor that contains killed Enterococcus faecalis. A gingipain activity inhibitor that contains killed Enterococcus faecalis.
BACKGROUND: Omalizumab is the only licensed drug that serves as a third-line treatment for chronic idiopathic urticaria (CIU). The optimum doses of omalizumab remain controversial. Therefore, this study aims to estimate the efficacy and safety of different doses of omalizumab in the treatment of CIU patients.
MATERIALS AND METHODS: Four databases were searched from the database's creation to April 8, 2023. Several keywords such as omalizumab and urticarias were used to retrieve related studies. The meta-analytical outcomes were analyzed in R 4.2.1 software and Stata 15.1 software. Cochrane risk-of-bias tool Ver. 2 was used to evaluate the risk of bias in randomized controlled trials (RCTs).
RESULTS: In total, 2331 patients were included. Five indexes were employed to assess, including weekly Itch Severity Score (ISS7), weekly Hive Severity Score (HSS7), weekly Urticaria Activity Score (UAS7), Dermatology Life Quality Index (DLQI), and adverse events (AE). A 300 mg dose of omalizumab was the optimum dose to treat CIU, followed by the 150 mg dose. Furthermore, 600 mg of omalizumab only showed a significant difference from the placebo in HSS7. No significant statistical difference was observed in AE. Meta-regression analysis revealed that time, as a covariate, was statistically significant in the comparison of omalizumab 150 mg with placebo.
CONCLUSION: 300 mg of omalizumab was the optimum dosage to treat CIU patients, with a 150 mg dose also exhibiting good efficacy. Further studies are required to explore the efficacy and safety of different doses of omalizumab in the treatment of CIU patients.
Patients allocated to treatment with Co-Amlessa® (starting FDC perindopril 4mg/indapamide 2,5mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria. Patients on previous perindopril and amlodipine therapy will be automatically assigned to Co-Amlessa® arm.
PROBLEM TO BE SOLVED: To obtain a make-up cosmetic having a graduation effect, while having natural and soft finish, by admixing a pearl powder under specific conditions. SOLUTION: This cosmetic contains 3-30wt.% of pearl powder of uniformly coated spherical particles with particle sizes of 0.01-0.05μm. The coated spherical powder preferably comprises 70-95wt.% of the pearl powder as the substrate and 5-30wt.% of the spherical powder. The pearl powder is obtained by coating the surface of mica with titanium oxide and coating the resultant mica titanium with a spherical powder on its surface. The pearl powder as the substrate is preferably mica titanium comprising 45-70wt.% of mica, 30-55wt.% of titanium oxide because the mica titanium can develop strong pearl effect. The effect to impart graduated shadow raises the position of cheekbones, and gives all over the face gloss, tenacity and sharpness and hide skin pores and wrinkles to give naturally finished make-up.
The present invention discloses a medicine for curing woman barrenness. In the present invention, a medicinal soup with semen persicae, safflower and other four Chinese herbal medicines which is a classic formulation in traditional Chinese medical science is used as a basic formulation. In order to enlarge the function of promoting blood circulation to remove blood stasis, rhizoma sparganii, zedoray rhizome, red sage root, motherwort and other medicines with the functions of promoting blood circulation, removing stasis, regulating emmenia and eliminating lump accumulating in the abdomen are additionally used. Bupleurum root, green tangerine peel, prepared nutgrass galingale rhizome, etc. are additionally used for regulating vital energy, resolving depression, alleviating pain and regulating emmenia. Patrinia, etc. are additionally used for clearing away heat and toxic materials, removing purulence and breaking stasis. Cassia bark is additionally used for invigorating the premodial energy of yang, warming the stomach and the spleen, removing internal cold and promoting blood circulation. The medicines are prepared into pure Chinese herbal granules through refined extraction and processing. The medicine of the present invention can be used for curing salpingemphraxis, uterine hypoplasia, ovulation failure, inadequate luteal function, endometriosis, myoma of uterus, ovarian cyst and other barrenness. The medicine of the present invention has obvious effect of curing barrenness. Simultaneously, the present invention which uses Chinese herbal medicines as basic raw materials has small toxic and side effect, convenient preparation, low price, easy popularization and easy use.
Anti-pediculosis treatments are disclosed which comprise formulations of one or more terpenes in aqueous solutions.  No resistance to the formulation disclosed has been observed.  When used on the scalp or body no extended dwell time is required.  The formulations do not have the unpleasant odours associated with prior art shampoo treatments for lice and are preferable on grounds of neurological safety.  Neurotoxins are the usual active ingredients associated with prior art treatments.  The formulations are directed towards providing topical preparations, which may be used on the scalp and hairy body parts, a spray for use on fabrics, a dipping solution for combs and a laundry additive.
Water-based exercise as a mode of aquatic exercise has been highlighted in the scientific literature. Research on different models of training, aerobic, muscle strength and combined (aerobic and muscle strength), have already demonstrated their beneficial effects on different physical abilities. Recent studies indicate benefits of water-based exercise for the population with metabolic diseases such as hypertension, type 2 diabetes, dyslipidemias and obesity. However, for subjects with metabolic syndrome (MS) there are few studies that investigated which training model in the aquatic environment could generate physical and metabolic improvements.

This study is characterized as a randomized clinical trial, which treated three intervention groups with physical exercise programs. A subsample participated in a period of eight weeks without physical exercise to characterize a control period. The subjects in this subsample were later randomized into the intervention groups.
Patients will be divided into two groups, and general anesthesia will be administered to all. Before extubation, one group will receive an external oblique intercostal nerve block, while the other group will receive an oblique subcostal transversus abdominis plane block. The randomization of the study will be carried out by a computer-generated randomization code (computer-generated) by a physician who will not be involved in patient follow-up. The interfascial plane block (either external oblique intercostal block or oblique subcostal block) will be provided to an anesthesiologist in a sealed envelope by an independent assistant staff member outside the study. The patient will not be aware of which block is applied. The anesthesiologist performing the block will not participate in the pain follow-up of the patients. Postoperative pain assessment and data collection will be conducted by another anesthesiologist unaware of the study.

For standardization, the block procedure will be performed by an experienced anesthesiologist who has completed at least 20 previous successful and uncomplicated procedures.
The present invention relates to crystalline human farnesyl diphosphate synthase (FPPS), to the three-dimensional structure of free FPPS as well as the three-dimensional structures of FPPS in complex with substrates such as IPP (isopentenyl diphosphate) and/or with inhibitors such as Zometa® or Aredia®. Further, methods for preparing crystals of human FPPS are described. According to the invention the crystals can be used to determine the structures of FPPS homologs mutants, complexes with ligands, FPPS crystal forms and similar molecules of unknown structure. The invention further relates to the use of FPPS crystals to select new FPPS ligands, e.g. by X-ray screening and to design and/or identify inhibitors against FPPS. Furthermore, the invention relates to NMR methods for selecting and/or identifying new low molecular weight binders to FPPS, which represent new therapeutic agents.
Two-dimensional ultrasound (2DUS) echocardiography is the main noninvasive method used to evaluate cardiac function in animal models of myocardial infarction (MI). However, 2DUS echocardiography does not capture regional differences in cardiac contractility since it relies on planar images to estimate left ventricular (LV) geometry and global function. Thus, the current study was designed to evaluate the efficacy of a newly developed 4-dimensional ultrasound (4DUS) method in detecting cardiac functional differences between two models of MI, permanent ligation (PL), and ischemia/reperfusion (I/R) in rats. We found that only 4DUS was able to detect LV global functional differences between the two models and that 4DUS-derived surface area strain accurately detected infarcted regions within the myocardium that correlated well with histological infarct size analysis. We also found that 4DUS-derived strain, which includes circumferential, longitudinal, and surface area strain, correlated with the peak positive of the first derivative of left ventricular pressure (+dP/dtmax). In conclusion, 4DUS strain echocardiography effectively assesses myocardial mechanics following experimentally induced ischemia in rats and accurately estimates infarct size as early as 1 day after injury. 4DUS also correlates well with +dP/dtmax, a widely used marker of cardiac contractility.
Erythropoietin (EPO) peptides and the use thereof for preparing epitope-specific anti-EPO antibodies are described. Also described are corresponding anti-EPO antibodies which take the form of polyclonal antibodies (antisera) or of monoclonal antibodies. These antibodies are suitable for purifying EPO, EPO derivatives or EPO peptides. The epitope-specific anti-EPO antibodies according to the invention can also be used for the detection of EPO and, in particular, for the epitope-specific detection of EPO. Additionally described are anti-idiotype antibodies which imitate a receptor region of EPO. Finally, pharmaceuticals which contain the EPO peptides, anti-EPO antibodies or anti-idiotype antibodies, and diagnostic aids for the detection of EPO or of anti-EPO antibodies, are described.
Recent studies have shown that microRNA-16-5p (miR-16-5p) plays a crucial role in the pathological mechanism of vascular calcification. Nevertheless, the expression profile of miR-16-5p in maintenance hemodialysis (MHD) patients who are predisposed to vascular calcification remains unknown. This study aims to investigate the potential associations between calcification risk and serum miR-16-5p expression among MHD patients. This cross-sectional study involved 132 MHD patients from the Dialysis Center of Beijing Friendship Hospital between 1 January 2019 and 31 December 2020. The degree of calcification in MHD patients was assessed using the Abdominal aortic calcification (AAC) score, and miR-16-5p expression was quantified using quantitative real-time polymerase chain reaction (qRT-PCR) with the 2-ΔΔCT method. Statistical analyses, including spearman correlation, linear regression and logistic regression analysis were used to explore the associations between laboratory parameters and AAC score. Calcifications were observed in 79(59.80%) patients. The linear regression showed a one-quartile decrease in miR-16-5p expression led to a significant increase in the AAC score by 5.336 (95% CI: 2.670-10.662, p = 0.000). Multivariate logistic regression analyses revealed that decreased miR-16-5p expression, reduced serum urea nitrogen, elevated white blood cell count, and longer dialysis vintage were significantly associated with an increased incidence of vascular calcification. The Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) of the miR-16-5p-based logistic regression model was 0.842 (95% CI: 0.771-0.913, p = 0.000). There was an independent association between miR-16-5p expression and calcification degree. Lower miR-16-5p expression levels seem to be a potential risk factor of vascular calcification in MHD patients.
PURPOSE:The titled cosmetic, containing polyoxypropylene butyl ehter and jujube oil, and having improved lubricity, and capable of protecting the hair from mechanical irritation in brushing and spreading over the hair surface uniformly with improved feeling of use. CONSTITUTION:An aerosol cosmetic for hair containing a polyoxypropylene butyl ether expressed by the formula (n is 30-50) and jujube oil. The content of the  compound expressed by the formula is 0.5-50wt%, and that of the jujube oil is  0.1- 15wt%. The compound expressed by the formula is nontoxic and has improved lubricity, solubility and stability in a propellant and hairdressing and protecting effects on the hair. The jujube oil reduces the critical surface tension of the hair and spreads uniformly on the surface of the hair with the compound expressed by the formula. The use of both components provide the titled cosmetic having good brushability and improved finish and feeling of use.
Participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named "Mei Ri Yi Jun" was produced by Wedge Pharmaceuticals.
This is a single-arm study with no intervention involved. Adults aged 18 or above from the community will be invited to fill out the same set of questionnaires on a total of two time points: baseline and two-week post-baseline.
PURPOSE: Heterotopic ossification (HO) can occur after hemiarthroplasty (HA) for femoral neck fractures (FNF). This study aimed to investigate the frequency and factors contributing to the development of HO after HA.
METHODS: The study included data from 92 of 183 patients (26 male and 66 female) who sustained FNF and underwent HA between April 2019 and January 2022. HO was identified on postoperative radiographic images. Patient background, operative duration, blood loss, and presence of free bone fragments immediately after surgery were compared between the HO and non-HO groups. Statistical analyses included the independent-sample t-test for continuous variables and the chi-squared test for categorical variables. A multivariate logistic regression analysis was performed using HO as an objective variable.
RESULTS: HO occurred in 50 of the 92 (54%) patients. There were no statistically significant differences in patient backgrounds. Univariate analysis revealed significantly longer mean operative duration and greater blood loss in the HO group. Free bone fragments in the immediate postoperative period were observed in 29 of 50 (58%) patients in the HO group and in 3 of 42 (7.1%) patients in the non-HO group, a statistically significant difference. Logistic regression analysis revealed that the presence of free bone fragments was an independent explanatory factor for HO development.
CONCLUSION: The presence of free bone fragments immediately after surgery may be significantly associated with the development of HO. Therefore, it is necessary to sufficiently remove such fragments during surgery because they may trigger HO.
This is a randomized controlled multicenter trial. Patients after in-hospital cardiac arrest are randomized either to standard therapy or to standard therapy in addition to mild therapeutic hypothermia. Mild therapeutic hypothermia is performed for 24 hours with a target temperature of 32-34°C. Inclusion criteria are: Adult patients which have been resuscitated after cardiac arrest in-hospital and who remain unconscious after restoration of spontanous circulation. Exclusion criteria are: severe cardiogenic shock, severe rhythm disorders, major surgery within the last 10 days, planned surgery within the next 24 hours afer resuscitation, active bleeding, suspicion od intracranial bleeding, severe infection, such as pneumonia or sepsis, a severe neurological deficit before cardiac arrest, an aquired immun deficency, pregnacy. The primary endpoint is mortality for all causes after six months. Secondary endpoints are neurological outcome after six months measured by the Glasgow-Pittsburgh Cerebral Performance scale, and in-hospital-mortality.